CRL - Public offerings

– Jim Foster, Chair, President & CEO, Announces Plans to Retire at the 2026 Annual Meeting of Shareholders in May 2026 After Distinguished 50-Year Career at Charles River – – Birgit Girshick, Current Executive Vice President & COO, Unanimously Appointed Next Chief Executive Officer, Also Effective in May 2026 – Charles River Laboratories International, Inc. (NYSE:CRL) announced today that James C. (Jim) Foster, Chair, President, and Chief Executive Officer (CEO), plans to retire, effective on May 5, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders. The Company's Board of Directors (Board) has unanimously appointed Birgit Girshick, current Executive Vice President and Ch

OKLAHOMA CITY, April 13, 2023 /PRNewswire/ -- Wheeler Bio, Inc., a boutique contract development and manufacturing organization (CDMO) specializing in process development and small batch CGMP production of therapeutic antibodies, announced the closing of their Series A financing round.  The round was co-led by Charles River Laboratories (NYSE:CRL) and Echo with participation from ATUM, Floating Point Advisors, Pine Ridge Ventures, Plains Venture Partners (a subsidiary of i2E), Seagull Capital, and Alloy Therapeutics. Wheeler Bio is building a disruptive CDMO model that is chan

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 3.750% senior notes due 2029 (the “2029 notes”) and $500 million in aggregate principal amount of its 4.000% senior notes due 2031 (the “2031 notes” and, together with the 2029 notes, the “notes”) in an unregistered offering. Charles River will use the gross proceeds of the offering of the notes to redeem its 5.5% senior notes due 2026 (the “2026 notes”), to fund, along with borrowings under its senior credit facilities, a portion of the purchase price for its proposed